CA3044066A1 - Protein kinase inhibitors - Google Patents
Protein kinase inhibitors Download PDFInfo
- Publication number
- CA3044066A1 CA3044066A1 CA3044066A CA3044066A CA3044066A1 CA 3044066 A1 CA3044066 A1 CA 3044066A1 CA 3044066 A CA3044066 A CA 3044066A CA 3044066 A CA3044066 A CA 3044066A CA 3044066 A1 CA3044066 A1 CA 3044066A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salts
- prodrugs
- lower alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433410P | 2016-12-13 | 2016-12-13 | |
| US62/433,410 | 2016-12-13 | ||
| US201762539785P | 2017-08-01 | 2017-08-01 | |
| US62/539,785 | 2017-08-01 | ||
| PCT/US2017/065847 WO2018111893A1 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044066A1 true CA3044066A1 (en) | 2018-06-21 |
Family
ID=61829613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044066A Pending CA3044066A1 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10174018B2 (enExample) |
| EP (1) | EP3555092A4 (enExample) |
| JP (1) | JP7077335B2 (enExample) |
| KR (1) | KR102582752B1 (enExample) |
| CN (1) | CN108473487B (enExample) |
| AU (1) | AU2017375949B2 (enExample) |
| CA (1) | CA3044066A1 (enExample) |
| WO (1) | WO2018111893A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473487B (zh) * | 2016-12-13 | 2021-08-03 | 普林斯顿药物研发公司 | 一种蛋白激酶抑制剂 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2020123277A1 (en) * | 2018-12-10 | 2020-06-18 | Princeton Drug Discovery Inc. | Protein kinase inhibitor prodrugs |
| KR102256804B1 (ko) * | 2019-02-26 | 2021-05-26 | 한국화학연구원 | N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20060021105A1 (en) * | 2004-07-29 | 2006-02-02 | Wilson Nick L | Ergonomic hand protection apparatus |
| PE20061394A1 (es) * | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
| WO2008033746A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090076025A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched dasatinib |
| WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| WO2010107791A2 (en) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Pyrazinoisoquinoline compounds |
| CA2764785C (en) * | 2009-06-08 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| CN102665756A (zh) * | 2009-10-01 | 2012-09-12 | Csl有限公司 | 费城染色体阳性白血病的治疗方法 |
| CN101891738B (zh) | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| EP2872159A2 (en) | 2012-07-13 | 2015-05-20 | Concert Pharmaceuticals Inc. | Deuterated carfilzomib |
| CA2904148A1 (en) | 2013-03-14 | 2014-10-02 | Concert Pharmaceuticals, Inc. | Deuterated pacritinib |
| CN104130250B (zh) | 2013-05-07 | 2016-06-22 | 郑州泰基鸿诺药物科技有限公司 | 氘代达沙替尼及其制备方法和应用 |
| CN104151321B (zh) * | 2013-05-15 | 2016-09-07 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US20170224688A1 (en) | 2016-02-04 | 2017-08-10 | Acerta Pharma B.V. | Methods of Using BTK Inhibitors to Treat Dermatoses |
| WO2017168454A2 (en) * | 2016-04-02 | 2017-10-05 | Sun Pharma Advanced Research Company Limited | Novel compounds as btk inhibitors |
| CN108473487B (zh) | 2016-12-13 | 2021-08-03 | 普林斯顿药物研发公司 | 一种蛋白激酶抑制剂 |
-
2017
- 2017-12-12 CN CN201780002746.8A patent/CN108473487B/zh active Active
- 2017-12-12 CA CA3044066A patent/CA3044066A1/en active Pending
- 2017-12-12 WO PCT/US2017/065847 patent/WO2018111893A1/en not_active Ceased
- 2017-12-12 KR KR1020197018970A patent/KR102582752B1/ko active Active
- 2017-12-12 JP JP2019551918A patent/JP7077335B2/ja active Active
- 2017-12-12 EP EP17879997.9A patent/EP3555092A4/en active Pending
- 2017-12-12 US US15/839,332 patent/US10174018B2/en active Active
- 2017-12-12 AU AU2017375949A patent/AU2017375949B2/en active Active
- 2017-12-12 US US15/839,534 patent/US20180099961A1/en not_active Abandoned
- 2017-12-12 US US15/839,469 patent/US10479786B2/en active Active
-
2018
- 2018-11-02 US US16/179,174 patent/US10556897B2/en active Active
-
2019
- 2019-12-19 US US16/721,142 patent/US11236080B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020503376A (ja) | 2020-01-30 |
| US20180099961A1 (en) | 2018-04-12 |
| WO2018111893A1 (en) | 2018-06-21 |
| KR20190091312A (ko) | 2019-08-05 |
| US20180099960A1 (en) | 2018-04-12 |
| US10479786B2 (en) | 2019-11-19 |
| CN108473487A (zh) | 2018-08-31 |
| US10174018B2 (en) | 2019-01-08 |
| US11236080B2 (en) | 2022-02-01 |
| JP7077335B2 (ja) | 2022-05-30 |
| US20200123148A1 (en) | 2020-04-23 |
| US20190071437A1 (en) | 2019-03-07 |
| CN108473487B (zh) | 2021-08-03 |
| AU2017375949B2 (en) | 2021-09-09 |
| EP3555092A1 (en) | 2019-10-23 |
| US20180099959A1 (en) | 2018-04-12 |
| EP3555092A4 (en) | 2020-05-13 |
| US10556897B2 (en) | 2020-02-11 |
| AU2017375949A1 (en) | 2019-05-23 |
| KR102582752B1 (ko) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11236080B2 (en) | Protein kinase inhibitors | |
| US10596174B2 (en) | Pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| AU2013300106B2 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| TW201815799A (zh) | 巨環激酶抑制劑 | |
| WO2017066193A1 (en) | Novel inhibitors of protein kinases | |
| US9586965B2 (en) | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases | |
| WO2021074251A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer | |
| HK1238243B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HK1238243A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HK1210471B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| WO2020123277A1 (en) | Protein kinase inhibitor prodrugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221207 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240903 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250909 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260206 |